BIO3 — Biotest AG Cashflow Statement
0.000.00%
HealthcareConservativeMid CapNeutral
- €1.33bn
- €1.80bn
- €515.60m
- 44
- 19
- 61
- 33
Annual cashflow statement for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -26 | -6 | -1.3 | -30 | -62.7 |
Depreciation | |||||
Non-Cash Items | 54.1 | 16.5 | 1.1 | 25 | 17.5 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -16.1 | -85.2 | -65.1 | -41.3 | 48 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 34.3 | -50 | -33.6 | -16.7 | 33.9 |
Capital Expenditures | -107 | -54.6 | -34.1 | -27 | -18.2 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -41.5 | 255 | 26.1 | 12.4 | -5.2 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -148 | 201 | -8 | -14.6 | -23.4 |
Financing Cash Flow Items | -1.1 | -15.2 | 2.7 | 0.1 | 3.6 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 55.2 | -111 | 40.5 | 42 | 22.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -58.7 | 39.6 | -1.1 | 10.5 | 33.1 |